123 related articles for article (PubMed ID: 32709317)
1. Rapid and efficient chiral method development for lamivudine and tenofovir disoproxil fumarate fixed dose combination using ultra-high performance supercritical fluid chromatography: A design of experiment approach.
Kurmi M; Jayaraman K; Natarajan S; Kumar GS; Bhutani H; Bajpai L
J Chromatogr A; 2020 Aug; 1625():461257. PubMed ID: 32709317
[TBL] [Abstract][Full Text] [Related]
2. A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form.
Kokkirala TK; Kancherla P; Alegete P; Suryakala D
Biomed Chromatogr; 2021 Aug; 35(8):e5121. PubMed ID: 33760252
[TBL] [Abstract][Full Text] [Related]
3. Simple thin layer chromatography-ultraviolet spectrophotometric method for quality assessment of binary fixed-dose-combinations of lamivudine/tenofovir disoproxil fumarate and lamivudine/zidovudine in tablet formulations.
Vaikosen EN; Kashimawo AJ; Soyinka JO; Orubu S; Elei S; Ebeshi BU
J Sep Sci; 2020 Jun; 43(11):2228-2239. PubMed ID: 32125772
[TBL] [Abstract][Full Text] [Related]
4. Stability behaviour of antiretroviral drugs and their combinations. 2: Characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry.
Kurmi M; Kushwah BS; Sahu A; Narayanam M; Singh S
J Pharm Biomed Anal; 2016 Jun; 125():245-59. PubMed ID: 27042808
[TBL] [Abstract][Full Text] [Related]
5. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.
Waitt C; Diliiy Penchala S; Olagunju A; Amara A; Else L; Lamorde M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():300-307. PubMed ID: 28651173
[TBL] [Abstract][Full Text] [Related]
6. A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets.
Godela R; Gummadi S
Ann Pharm Fr; 2021 Nov; 79(6):640-651. PubMed ID: 34019910
[TBL] [Abstract][Full Text] [Related]
7. Determination of enantiomeric impurity of tenofovir disoproxil fumarate on a cellulose tris(3,5-dichlorophenyl-carbamate) chiral stationary phase and the characterization of its related substances.
Nguyen BT; Le TA; Mai XL; Nguyen TNV; Phan TD; Kang JS; Kim KH
J Sep Sci; 2021 May; 44(10):2029-2036. PubMed ID: 33682357
[TBL] [Abstract][Full Text] [Related]
8. Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design.
Tibalinda P; Sempombe J; Shedafa R; Masota N; Pius D; Temu M; Kaale E
Heliyon; 2016 Dec; 2(12):e00207. PubMed ID: 27942608
[TBL] [Abstract][Full Text] [Related]
9. Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet.
Alexander AJ; Zhang L; Hooker TF; Tomasella FP
J Pharm Biomed Anal; 2013 May; 78-79():243-51. PubMed ID: 23507686
[TBL] [Abstract][Full Text] [Related]
10. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.
Anderson MS; Gilmartin J; Fan L; Yee KL; Kraft WK; Triantafyllou I; Reitmann C; Guo Y; Liu R; Iwamoto M
Antivir Ther; 2019; 24(6):443-450. PubMed ID: 31433304
[TBL] [Abstract][Full Text] [Related]
11. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
[TBL] [Abstract][Full Text] [Related]
12. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
13. Purification of drug degradation products supported by analytical and preparative supercritical fluid chromatography.
Noireau A; Lemasson E; Mauge F; Petit AM; Bertin S; Hennig P; Lesellier É; West C
J Pharm Biomed Anal; 2019 Jun; 170():40-47. PubMed ID: 30904738
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Dubrocq G; Rakhmanina N
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):773-779. PubMed ID: 29985071
[TBL] [Abstract][Full Text] [Related]
15. Generic chiral method development in supercritical fluid chromatography and ultra-performance supercritical fluid chromatography.
De Klerck K; Vander Heyden Y; Mangelings D
J Chromatogr A; 2014 Oct; 1363():311-22. PubMed ID: 24953426
[TBL] [Abstract][Full Text] [Related]
16. Analytical separation of four stereoisomers of luliconazole using supercritical fluid chromatography: Thermodynamic aspects and simulation study with chiral stationary phase.
Pandya PA; Shah PA; Shrivastav PS
J Chromatogr A; 2020 Aug; 1625():461299. PubMed ID: 32709342
[TBL] [Abstract][Full Text] [Related]
17. A fast and sensitive method for the separation of carotenoids using ultra-high performance supercritical fluid chromatography-mass spectrometry.
Jumaah F; Plaza M; Abrahamsson V; Turner C; Sandahl M
Anal Bioanal Chem; 2016 Aug; 408(21):5883-5894. PubMed ID: 27349917
[TBL] [Abstract][Full Text] [Related]
18. Development of an orthogonal method for mometasone furoate impurity analysis using supercritical fluid chromatography.
Wang Z; Zhang H; Liu O; Donovan B
J Chromatogr A; 2011 Apr; 1218(16):2311-9. PubMed ID: 21376330
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
